The New York-based auctioneer of fine art and jewelry, Sotheby’s (BID), announced on Monday that it had named a new CFO.
It was reported that William Sheridan, executive VP and CFO, is leaving the company after 17 years of employment; Patrick McClymont, a partner and managing director at Goldman Sachs (GS), will succeed Mr. Sheridan effective on October 7th. Sheridan commented, “I have had the privilege of working with a highly skilled, highly professional finance, investor relations and information technology team at Sotheby’s that I invested in and helped build, and they deserve an enormous amount of�credit�for all that we accomplished. It has been a true pleasure to be part of Sotheby’s and now I look forward to spending more time with my family and focusing on charitable work.”
Top 5 Stocks To Invest In Right Now: Dreamworks Animation SKG Inc. (DWA)
DreamWorks Animation SKG, Inc. engages in the development, production, and exploitation of animated feature films and characters worldwide. It provides animated feature films and characters for the theatrical, home entertainment, television, and merchandising and licensing markets. The company also offers television specials and series, live entertainment properties, online virtual worlds, and related consumer products. It has approximately 21 animated feature films, including Shrek the Third, Shrek 2, and Madagascar. The company has strategic alliances with McDonald?s, Hewlett-Packard, Intel, and Samsung. DreamWorks Animation SKG, Inc. was founded in 1985 and is headquartered in Glendale, California.
Advisors' Opinion:- [By Peter Graham]
On the news front and in late September,�JAKKS Pacific announced�that�Disguise, Inc, its Halloween costume division, had secured a licensing agreement with Dreamworks Animation Skg Inc (NASDAQ: DWA) to produce Halloween costumes and accessories based on their portfolio of top entertainment brands. The agreement includes rights to create Halloween costumes based on a multitude of DreamWorks Animation properties, including upcoming movie releases and heritage properties such as SHREK.
- [By Steve Symington]
Thanks to�last weekend's�dismal box office debut�of DreamWorks Animations'� (NASDAQ: DWA ) �Turbo,�we may get the chance to find out.
Top 10 Information Technology Stocks To Buy For 2014: Stone Energy Corporation(SGY)
Stone Energy Corporation, an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and operation of oil and gas properties in the Gulf of Mexico and the Appalachia region. As of December 31, 2010, it had estimated proved oil and natural gas reserves of approximately 473.9 billion cubic feet of gas equivalent. The company was founded in 1993 and is headquartered in Lafayette, Louisiana with additional offices in New Orleans, Louisiana; Houston, Texas; and Morgantown, West Virginia.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap Energy XXI (Bermuda) Limited (NASDAQ: EXXI)�announced a deal to acquire�EPL Oil & Gas Inc (NYSE: EPL) to create the largest publicly held independent oil producer on the Gulf of Mexico shelf, meaning it might be a good idea to look at other small cap Gulf oil stocks like W&T Offshore, Inc (NYSE: WTI), Stone Energy Corporation (NYSE: SGY) and Contango Oil & Gas Company (NYSEMKT: MCF). Energy XXI�� CEO John Schiller has talked about the details of the acquisition�with Jim Cramer on CNBC's "Mad Money" and he noted that��EPL Oil & Gas offers areas of expertise that EXXI currently lacks. However, investors who missed out on�yesterday�� 29% surge for EPL Oil & Gas�may want to check out these other small cap Gulf Oil stocks:
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Tuesday, energy shares were relative leaders, up on the day by about 1.41 percent. Meanwhile, top gainers in the sector included Stone Energy (NYSE: SGY), up 9 percent, and Westmoreland Coal Co (NYSE: WLB), up 7.8 percent. Industrials services shares gained by just 0.02 percent in Tuesday's trading.
Top 10 Information Technology Stocks To Buy For 2014: Valassis Communications Inc.(VCI)
Valassis Communications, Inc., together with its subsidiaries, operates as a media and marketing services company primarily in the United States and Europe. Its Shared Mail segment combines the individual print advertisements of various clients into a single shared mail package and distributes the shared mail advertising products to approximately 70 million U.S. households primarily on a weekly basis through the United States Postal Service (USPS). This segment also offers solo mail and other products and services, including list procurement, addressing, processing, and the distribution of brochures and circulars; ancillary services, such as list rentals; and direct mail advertising solutions for local neighborhood businesses. It primarily serves grocers, restaurants, drug stores, discount and department stores, home furnishing stores, and other retailers. The company?s Neighborhood Targeted segment is involved in the print and media placement of traditional free-standing solo insert formats and specialty print promotion products; offers newspaper-delivered or direct-to-door sampling products that give manufacturers the ability to cover approximately 60 million households; and helps clients to run their promotional advertising directly on the pages of newspapers by brokering advertising space. The company?s Free-standing Inserts segment prints and distributes four-color booklets containing promotions, primarily coupons from multiple clients through newspapers and shared mails. Its International, Digital Media, and Services segment provides coupon clearing, analytical promotion information management products, and marketing services for retailers and consumer-packaged goods manufacturers; and promotion security and consulting services, as well as produces direct-mail programs based on multiple data sources, including frequent shopper card data. Valassis Communications, Inc. was founded in 1970 and is headquartered in Livonia, Michigan.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Valassis Communications (NYSE: VCI) shot up 22.16 percent to $34.57 after the company agreed to be acquired by Harland Clarke Holdings Corp for $34.04 per share in cash. - [By Alex Planes]
What: Shares of Valassis Communications (NYSE: VCI ) crashed by nearly 15% this morning but have since clawed their way back to a loss of about 8%, on a double whiff on first-quarter earnings and an underwhelming set of forward guidance.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Wednesday’s session are Valassis Communications Inc.(VCI) and Gogo Inc.(GOGO)
Valassis agreed to be acquired by Harland Clarke Holdings Corp. in a deal valuing the coupon publisher at roughly $1.31 billion that the companies expect will create a leading diversified payment and marketing-services company. Shares surged 21% to $34.29 premarket.
Top 10 Information Technology Stocks To Buy For 2014: Crestwood Equity Partners LP (CEQP)
Crestwood Equity Partners LP, incorporated on March 7, 2001, is a master limited partnership. The Company owns the general partner interest (including the distribution rights) and an approximate 4% limited partner interest of Crestwood Midstream.
In addition, the Company's operations include a natural gas storage business in Texas and a natural gas liquid (NGL) and crude oil supply and logistics business that serves customers in the United States and Canada. On October 7, 2013, Crestwood Midstream Partners LP merged into Inergy Midstream, L.P.
Advisors' Opinion:- [By Aimee Duffy]
With Kinder Morgan's acquisition of Copano Energy officially in the bag, all eyes are on the newest big deal in the midstream world: the merger of Crestwood Midstream Partners (NYSE: CMLP ) and Inergy (NYSE: CEQP ) . In this video, Fool.com contributor Aimee Duffy takes a look at this $7 billion deal, and explains what the ownership structure looks like at the new, yet-to-be-named entity.
- [By Dan Caplinger]
On Tuesday, Inergy (NYSE: CEQP ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.
Top 10 Information Technology Stocks To Buy For 2014: Incyte Corporation(INCY)
Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Advisors' Opinion:- [By Maxx Chatsko]
Pfizer will turn its immediate focus to Xeljanz, a novel JAK3 inhibitor, as it awaits phase 3 data from ertugliflozin several years from now. The drug class has swept the pharmaceutical industry by storm. Novartis (NYSE: NVS ) and Eli Lilly are developing JAK1 and JAK2 inhibitors for several applications with Incyte (NASDAQ: INCY ) , while a handful of other companies have molecules of their own. While companies have high hopes for the cancer-fighting potential of JAK inhibitors, such as Jakafi from Novartis and Incyte, the biggest opportunities may lie in the immunology market.
- [By John McCamant]
Incyte Pharmaceuticals (INCY) recently held their quarterly conference call. Importantly, sales for Jakafi��n advanced compound used for the treatment of patients with intermediate or high-risk myelofibrosis (MF)��et or exceeded Wall Street's expectations.
- [By Paul Ausick]
Big earnings winners: Incyte Corp. (NASDAQ: INCY) up 34.4% to $36.02 on a successful drug trial, Target Corp. (NYSE: TGT) down 3.5% to $65.54 on weak earnings and lowered outlook, and Lowe�� Companies Inc. (NYSE: LOW ) up 4.4% at $46.01 on strong earnings and an improved outlook.
- [By Ben Levisohn]
Somaiya points to Gilead Sciences, Alexion Pharmaceuticals (ALXN), Celgene and Incyte (INCY) as the biotech companies most likely to beat earnings:
Top 10 Information Technology Stocks To Buy For 2014: ARIAD Pharmaceuticals Inc.(ARIA)
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company?s lead cancer product, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer, and non-small cell lung cancer. Its product pipeline also includes ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma. In addition, the company focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. Further, it licenses its ARGENT cell-sign aling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products, and to conduct drug discovery research. The company has collaboration and license agreements with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent restenosis of injured vessels. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.
Advisors' Opinion:- [By Bryan Murphy]
Considering I'm tired of saying it, there's a good chance you're tired of hearing it. Yet, if it needs to be said, then it needs to be said - Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is acting like it wants to go higher, and taking that hint in the recent past has paid off well, even if only temporarily.
- [By Bryan Murphy]
The great part about trading is the same thing that can make it a miserable game to play... nothing lasts forever. If you can spot the points in time when the winds blowing a stock are about to change, you can make or save a fortune. If you miss those subtle clues, however, you can lose... big-time. Enter Arotech Corporation (NASDAQ:ARTX) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Both have been well-watched stocks of late, and for food reason - both are big movers, in one direction or the other. Now, however, both ARIA and ARTX� are poised to move in a new direction - opposite directions - and traders looking for a good opportunity may want to take a closer look at both [which is what you're about to do].
- [By Bryan Murphy]
If you're looking for a riches-to-rags-back-to-riches story to trade, then Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) may well be the first and last name to consider. This biotech stock has gone from being on top of the world to the bottom of the barrel to, well, maybe starting to claw its way back toward the top of the heap as of this week. While the rebound from ARIA is still a little fuzzy, the scales seem to have finally tipped in a slightly-bullish direction.
- [By Brian Orelli]
The other downside of this investment strategy is that it's not always clear when a decision will happen. Recently, the FDA has been making decisions well ahead of the goal set by the Pharmaceutical Drug User Fee Act, commonly referred to as the PDUFA date. ARIAD Pharmaceuticals� (NASDAQ: ARIA ) , for instance, gained early approval for its leukemia drug Iclusig last year, and shares traded down by double digits after the widely expected announcement.
Top 10 Information Technology Stocks To Buy For 2014: Xyratex Ltd.(XRTX)
Xyratex Ltd provides modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. It offers enterprise data storage solutions that include storage enclosures, which provide a common technology platform that reduces qualification time for original equipment manufacturer (OEM) customers and includes management interface software, standardized across enclosures, and provides easy integration as new platforms; integrated application platforms that comprise embedded storage platforms, which incorporate embedded server modules into its storage enclosures; and HPC Solutions that consolidate controllers, storage enclosures, application platforms, operating system, data protection, Lustre File System, and management software into a optimized scale-out storage platform that can be deployed in hours rather than weeks. The company also designs and manufactures a range of process test systems, which incorporate mechanical and electronic hardware, and firmware for controlling the HDD operating environment during the formatting of the disk drive. In addition, it provides automated solutions comprising substrate and media inspection systems; servo track writers and related subassemblies; and head testing systems that test and process HDD components throughout the manufacturing process. The company markets and sells its products primarily to OEMs and disk drive manufacturers, as well as to other companies in North America, Asia, and Europe. Xyratex Ltd was founded in 1966 and is headquartered in Havant, the United Kingdom.
Advisors' Opinion:- [By Jonathan Fishman]
Two weeks ago an SA contributor, Kingsley Park Capital, pointed out that shares of Xyratex (XRTX) have a 70% upside. I suggest KPC is being conservative. I think its opinion is priceless, but I would like to offer my financial model to support this thesis and show that the moment the market realizes what's going on, XRTX should be worth $20-$30 a share a year or so from now. Let's get started.
- [By Sue Chang and William L. Watts]
Xyratex Ltd. (XRTX) �dropped 6.7%. The company late Thursday reported a 70% drop in third-quarter earnings and offered a somewhat downbeat fourth-quarter forecast. The U.K.-based maker of data-storage and manufacturing equipment said it expects fourth-quarter results to range between a loss of four cents and a profit of 20 cents on revenue of $190 million to $220 million. Analysts surveyed by Thomson Reuters had produced a forecast for profit of 16 cents on revenue of $218 million. Shares are up by around 43% for the year to date.
- [By Monica Gerson]
Analysts expect Xyratex (NASDAQ: XRTX) to post its Q3 earnings at $0.05 per share on revenue of $209.31 million. Xyratex shares gained 0.18% to close at $11.16 yesterday.
- [By Seth Jayson]
Xyratex (Nasdaq: XRTX ) reported earnings on July 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended May 31 (Q2), Xyratex beat expectations on revenues and beat expectations on earnings per share.
No comments:
Post a Comment